Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.33 |
| ▸ | P2RX2 | Q9UBL9 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13031454 | 0.87 | PTGS2 (0.35) | PTGS2PTGS1GRIN1GRIN2BP2RX3 | |
| SCHEMBL13031380 | 0.86 | GRIN1 (0.35) | PTGS2PTGS1GRIN1GRIN2BP2RX3 | |
| SCHEMBL3589661 | 0.84 | TLR8 (0.40) | TLR9TLR8TLR7NPC1RAB9A | |
| SCHEMBL13031140 | 0.82 | PTGS2 (0.36) | PTGS2PTGS1GRIN1GRIN2BP2RX3 | |
| SCHEMBL13031159 | 0.82 | GRIN2B (0.35) | NPC1RAB9APTGS2PTGS1GRIN1 | |
| SCHEMBL13031165 | 0.82 | GRIN2B (0.37) | NPC1RAB9APTGS2PTGS1GRIN1 | |
| SCHEMBL13031205 | 0.82 | GRIN2B (0.35) | NPC1RAB9APTGS2PTGS1GRIN1 | |
| SCHEMBL13031207 | 0.82 | SCN9A (0.38) | GRIN1GRIN2B | |
| SCHEMBL13031169 | 0.81 | GRIN1 (0.38) | PTGS2PTGS1GRIN1GRIN2BALDH1A1 | |
| SCHEMBL13031195 | 0.81 | PTGS2 (0.36) | NPC1RAB9APTGS2PTGS1GRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | disclosed |
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | disclosed |
| WO-2007070433-A2 | 2-ARYLTHIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | CXCR3, CXCR1, CXCR2 | TLR9 32/4885TLR8 266/4885TLR7 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.